Objective To explore the main X-ray feature of the non-metallic foreign body in lower respiratory tract in order to improve the diagnostic accuracy.Methods X-ray findings of non-metallic body in lower respiratory in 150 cases proved by tracheobronchoscopy were retrospectively analyzed.The changes of heartshadow,mediastinum pulmotransparency and diaphragm during the procedure of deepbreath were observed under fluoroscoopy in different position,based on that the location of foreign body was evaluated.Results The distribution of foreign bodies in all patients included:38 cases in trachea,81 cases in right bronchus (25 cases in right primary bronchus,4 cases in upper lobar bronchus,5 cases in middle lobar bronchus,47 cases in lower lobar bronchus and segmental brouchus),31 cases in left bronchus (13 cases in left primary bronchus,2 cases in upper lobar bronchus and 16 cases in lower lobar bronchus).Because of the anatomical difference,the foreign bodies usually saw in right lower lobar bronchus.Conclusion Those patients who were suspected with foreign bodies in lower respiratory tract should be routinly examined by X-ray including fluoroscopy which is of important value in localized diagnosis of non-metallic foreign body in lower respiratory tract.

Objective To improve the recognition of diabetic pedipathy through analyzing the X-ray findings of 20 cases.Methods Total 850 patients of diabetic mellitus were collected since 1985, of them,there were 20 cases with the complications of osteoarticulation or soft tissue of foot. The X-ray findings combined with clinical information were analysed.Results X-ray characters included:(1) osteoporosis in 20; (2) symmetrical atrophy of diaphysis in 14;(3) osseous absorption and destruction on the distal end of the bones in 11;(4) osteoarthritis in 7;(5) Charcot articulation in 2;(6) soft tissue swelling in 20, 5 of them having calcified vessels in area of metatarsus and phalanx.Conclusion For the patieuts with long-term diabetes without regular treatments, with repeating infection and even developing to obstinate ulceration on foot, the possible of diabetic pedipathy should be concerned. In order to obtain early diagnosis and effective therapy, it is necessary to take X-ray examination.

Claudin18.2(CLDN18.2)is a tight junction protein that is overexpressed in a variety of solid tumors such as gastrointestinal cancer and oesophageal cancer.It has been identified as a promising target and a potential biomarker to diagnose tumor,evaluate efficacy,and determine patient prognosis.TST001 is a recombinant humanized CLDN18.2 antibody that selectively binds to the extracellular loop of human Claudin18.2.In this study,we constructed a solid target radionuclide zirconium-89(89Zr)labled-TST001 to detect the expression of in the human stomach cancer BGC823CLDN18.2 cell lines.The[89Zr]Zr-des-ferrioxamine(DFO)-TST001 showed high radiochemical purity(RCP,＞99％)and specific activity(24.15±1.34 GBq/μmol),and was stable in 5％human serum albumin,and phosphate buffer saline(＞85％RCP at 96 h).The EC50 values of TST001 and DFO-TST001 were as high as 0.413±0.055 and 0.361±0.058 nM(P＞0.05),respectively.The radiotracer had a significantly higher average standard uptake values in CLDN18.2-positive tumors than in CLDN18.2-negative tumors(1.11±0.02 vs.0.49±0.03,P=0.0016)2 days post injection(p.i.).BGC823CLDN18.2 mice models showed high tumor/muscle ratios 96 h p.i.with[89Zr]Zr-DFO-TST001 was much higher than those of the other imaging groups.Immunohistochemistry results showed that BGC823CLDN18.2 tumors were highly positive(+++)for CLDN18.2,while those in the BGC823 group did not express CLDN18.2(-).The results of ex vivo biodistribution studies showed that there was a higher distribution in the BGC823CLDN18.2 tumor bearing mice(2.05±0.16％ID/g)than BGC823 mice(0.69±0.02％ID/g)and blocking group(0.72±0.02％ID/g).A dosimetry estimation study showed that the effective dose of[89Zr]Zr-DFO-TST001 was 0.0705 mSv/MBq,which is within the range of acceptable doses for nuclear medicine research.Taken together,these re-sults suggest that Good Manufacturing Practices produced by this immuno-positron emission tomog-raphy probe can detect CLDN18.2-overexpressing tumors.